Acuta Capital Partners’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Acuta Capital Partners’s Portfolio KRTX Stock Details KRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-5,000	Closed	-$508K	–	59
2020 Q4	$508K	Sell	5,000 -8,500	-63%	-$788K	0.14%	48
2020 Q3	$1.04M	Sell	13,500 -64,500	-83%	-$5.5M	0.28%	40
2020 Q2	$8.69M	Buy	78,000 +22,000	+39%	+$1.91M	2.51%	14
2020 Q1	$4.03M	Hold	56,000	–	–	1.95%	20
2019 Q4	$4.22M	Buy	+56,000	New	+$2.45M	1.04%	23

Other funds holding KRTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

PBPIA

Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Acuta Capital Partners's KRTX Position: Q1 2021 in Review

Acuta Capital Partners sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2021, closing a stake of 5,000 shares — an estimated $508K sold.

Acuta Capital Partners first reported a position in KRTX in Q4 2019 and held it in 5 quarters. The position peaked at $8.69M in Q2 2020. 157 funds tracked by Wall St. Rank hold KRTX as of Q1 2021.

Acuta Capital Partners reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Acuta Capital Partners sold 5,000 Karuna Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $508K.
Acuta Capital Partners first reported a position in Karuna Therapeutics, Inc. Common Stock in Q4 2019 and held it in 5 quarters.
Acuta Capital Partners's Karuna Therapeutics, Inc. Common Stock position peaked at $8.69M in Q2 2020.
157 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Acuta Capital Partners's 13F filing for Q1 2021, filed 17 May 2021.